GJA1 and neoplasm: Carboxyl‐terminal Cx43 peptidomimetics demonstrated potential in addressing resistance to TMZ therapy by modulating intercellular junctional activity and downstream molecular signaling pathways between tumor cells and surrounding cells [23].